Cargando…
Short-Term Administration of Serelaxin Produces Predominantly Vascular Benefits in the Angiotensin II/L-NAME Chronic Heart Failure Model
In patients hospitalized with acute heart failure, temporary serelaxin infusion reduced 6-month mortality through unknown mechanisms. This study therefore explored the cardiovascular effects of temporary serelaxin administration in mice subjected to the angiotensin II (AngII)/L-NG-nitroarginine meth...
Autores principales: | McCarthy, Joseph C., Aronovitz, Mark, DuPont, Jennifer J., Calamaras, Timothy D., Jaffe, Iris Z., Blanton, Robert M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034497/ https://www.ncbi.nlm.nih.gov/pubmed/30062150 http://dx.doi.org/10.1016/j.jacbts.2017.03.011 |
Ejemplares similares
-
β-Arrestin–Mediated Angiotensin II Type 1 Receptor Activation Promotes Pulmonary Vascular Remodeling in Pulmonary Hypertension
por: Ma, Zhiyuan, et al.
Publicado: (2021) -
Mixed linage kinase 3 functions as a cGMP-dependent protein kinase I alpha substrate and regulates blood pressure and cardiac remodeling in vivo
por: Calamaras, Timothy, et al.
Publicado: (2015) -
Differences in the renal antifibrotic signaling of serelaxin and zaprinast
por: Wetzl, Veronika, et al.
Publicado: (2015) -
Natriuretic Peptide Receptor-C Protects Against Angiotensin II-Mediated Sinoatrial Node Disease in Mice
por: Mackasey, Martin, et al.
Publicado: (2018) -
Acute atrial tachyarrhythmia induces angiotensin II type 1 receptor-mediated oxidative stress and microvascular flow abnormalities in the ventricles
por: Goette, Andreas, et al.
Publicado: (2009)